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Abstract
Background: Vitamin D insufficiency may be associated with depressive symptoms in non-pregnant adults. We
performed this study to evaluate whether low maternal vitamin D levels are associated with depressive symptoms
in pregnancy.
Methods: This study was a secondary analysis of a randomized trial designed to assess whether prenatal omega-3
fatty acid supplementation would prevent depressive symptoms. Pregnant women from Michigan who were at risk
for depression based on Edinburgh Postnatal Depression Scale Score or history of depression were enrolled.
Participants completed the Beck Depression Inventory (BDI) and Mini International Neuropsychiatric Interview at
12–20 weeks, 26–28 weeks, 34–36 weeks, and 6–8 weeks postpartum. Vitamin D levels were measured at 12–20
weeks (N = 117) and 34–36 weeks (N = 112). Complete datasets were available on 105 subjects. Using regression
analyses, we evaluated the relationship between vitamin D levels with BDI scores as well as with MINI diagnoses of
major depressive disorder and generalized anxiety disorder. Our primary outcome measure was the association of
maternal vitamin D levels with BDI scores during early and late pregnancy and postpartum.
Results: We found that vitamin D levels at 12–20 weeks were inversely associated with BDI scores both at 12—20
and at 34–36 weeks’ gestation (P < 0.05, both). For every one unit increase in vitamin D in early pregnancy, the
average decrease in the mean BDI score was .14 units. Vitamin D levels were not associated with diagnoses of
major depressive disorder or generalized anxiety disorder.
Conclusions: In women at risk for depression, early pregnancy low vitamin D levels are associated with higher
depressive symptom scores in early and late pregnancy. Future investigations should study whether vitamin D
supplementation in early pregnancy may prevent perinatal depressive symptoms.
Trial registration: https://clinicaltrials.gov/ Registration Number: NCT00711971
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Background
Antenatal depression may complicate up to 10–37 % of
pregnancies, while as many as 27–54 % of pregnancies
are complicated by antenatal anxiety [1–3]. Depression
in pregnancy and postpartum is associated with signifi-
cant morbidity [4, 5]. For example, perinatal depression
has been associated with impaired mother-infant bond-
ing and has also been associated with adverse outcomes
of pregnancy, such as preterm birth, IUGR, and low
birth weight [5–10]. In addition, depressive symptoms
during pregnancy have been shown to be associated ma-
ternal morbidities such as increased risk for preeclamp-
sia and operative deliveries [11].
It has been hypothesized that nutritional deficiencies
may increase risk for depression [12]. For instance, a
systematic review and meta-analysis of observational
studies involving 31,424 non-pregnant adults found low
vitamin D levels to be significantly associated with clin-
ical diagnoses of depression [13]. Vitamin D is obtained
by ingestion of vitamin D-containing foods or produced
endogenously by the skin after exposure to ultraviolet B
sunlight. Its relationship to depression was initially sug-
gested based upon epidemiologic studies that noted an
increase in depressive symptoms during winter months
[14]. One hypothesized physiologic mechanism through
which Vitamin D may act to affect depressive symptoms
has emerged with the understanding that vitamin D acts
as a neuroactive hormone, in addition to its role as a fat-
soluble vitamin [15]. Supporting this concept, Eyles et al.
demonstrated that vitamin D receptors are broadly dis-
tributed throughout the human brain [16] and animal
studies have found that vitamin D deficiency or dietary
manipulation/addition of vitamin D alters neurotransmit-
ters that are known to be involved in depressive symptoms
and depression [17–20]. Vitamin D may also play a role in
neuroimmunomodulation and neuroplasticity, a proposed
mechanism for the observed effect on mood [21].
There have been a number of studies in pregnant and
postpartum women suggesting that this association ex-
ists in this population as well. For example, in a cohort
of pregnant African-American women who were not se-
lected based on predisposition to depression, Cassidy-
Bushrow found early pregnancy low vitamin D levels to
be associated with mid-pregnancy symptoms of depres-
sion [22]. In a follow-up study of a subset of this cohort,
the authors also demonstrated an association of low
early pregnancy vitamin D levels with postpartum de-
pressive symptoms [23]. Similarly, Brandenbarg et al.
found an association between low early pregnancy vitamin
D levels and depressive symptoms measured at 16 weeks
gestation [24]. The more recent Huang et al., study exam-
ined the association 25 OH vitamin D levels measured at
15 weeks gestation with depression and anxiety symptoms
measured at that same time point [25].
Several studies have evaluated the association of vita-
min D levels with postpartum symptoms of depression.
Robinson, et al., in an unselected Australian cohort of
Caucasian women, found vitamin D levels at 18 weeks’
gestation to be associated with postnatal depressive
symptoms measured at 3 days postpartum [26]. Simi-
larly, Gur, et al., found a significant associated between
mid-pregnancy vitamin D levels and depression and de-
pression screen scores measured longitudinally in the
postpartum period among healthy women who were not
considered at risk for depression [27]. In a longitudinal
study carried out in the postnatal period, Murphy et al.
found an association between vitamin D levels <32 ng/ml
measured monthly for 7 months postpartum and depres-
sion symptom scores at these same time points [28]. By
contrast, the recent Nielsen case-control Danish National
Birth Cohort found that high levels of vitamin D in mid
pregnancy were associated with antidepressant use in the
postpartum period, an unexpected finding [29].
We conducted this study to evaluate whether plasma
vitamin D levels, measured in early and late pregnancy
were associated with depression symptom scores at 3 time
points during pregnancy and at 6–8 weeks postpartum.
This study differs from previously-reported investigations
in that our subjects were selected based on predisposition
to depression and both 25 [OH] vitamin D and depression
scores were measured at several time points. We mea-
sured depressive symptom scores at several time points,
using the Beck Depression Inventory to assess the severity
of depressive symptoms over time [30–32]. We hypothe-
sized that lower vitamin D levels during pregnancy would
be associated with higher depression symptom scores dur-
ing pregnancy and at 6–8 weeks postpartum.
Methods
Study design
This study is a secondary analysis of the data and blood
samples of a cohort of women who had enrolled in the
Mothers, Omega-3 & Mental Health Study trial, a pro-
spective, double blind, placebo-controlled, randomized con-
trolled trial designed to assess whether omega-3 fatty acid
supplementation during pregnancy would prevent antenatal
and postpartum depressive symptoms among pregnant
women at risk for depression. The protocol for this study
has been previously described [33]. The primary aim of this
secondary analysis was to determine whether low vitamin
D during pregnancy is associated with depressive symptoms
as assessed by the Beck Depression Inventory score at three
time points during pregnancy. As a secondary aim of this
study, we evaluated whether vitamin D levels were associ-
ated with Mini International Neuropsychiatric Interview
diagnoses of major depressive disorder (MDD), generalized
anxiety disorder (GAD), or anxiety symptoms (MINI anx-
iety subtest, question 1a) [34].
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Study population and protocol
Between October 2008 and May 2011 we enrolled 126
pregnant women at risk for depression from prenatal
clinics associated with The University of Michigan
Hospital in Ann Arbor, Michigan, and St. Joseph Mercy
Hospital in Ypsilanti, Michigan. We followed them pro-
spectively throughout pregnancy (12–20 weeks [visit 1],
26–28 weeks [visit 2], and 34–36 weeks [visit 3]) and at
6–8 weeks postpartum [visit 5]. Women were invited to
enroll based on risk factors for perinatal depression, in-
cluding a past history of depression or postpartum de-
pression, or an Edinburgh Postnatal Depression Scale
(EPDS) score of 9–19. The EPDS, used to screen for de-
pression risk in this study, has been accepted as a valid
and reliable 10-item measure of perinatal mood [35]. Al-
though a cut-off score of 11 is commonly used to screen
for risk for major depression, EPDS cutoff scores as low
as 9–10 have been shown to predict depression risk
[3, 36–38]. We chose to use a cutoff value of 9 be-
cause we aimed to enroll women at risk for depression
who however were not overtly depressed. Therefore,
women with scores between a 9 and 19 (at risk for depres-
sion or mildly depressed) on the EPDS were eligible for
randomization; women with scores > 19 were considered
severely depressed and were ineligible for randomization.
Other inclusion criteria were: age ≥ 18 years, singleton
gestation, and gestational age between 12–20 weeks. Add-
itional exclusion criteria were: history of bleeding disorder,
thrombophilia requiring anticoagulation, multiple gestation,
bipolar disorder, current major depressive disorder, current
substance abuse, lifetime substance dependence or schizo-
phrenia. Women were also ineligible if they were taking
omega-3 fatty acid supplements, antidepressant medica-
tions, or eating more than 2 fish meals per week [33]. All
participating women were taking prenatal vitamins, which
typically contain approximately 400 IU vitamin D [39]. Par-
ticipants were not excluded from initiating antidepressant
medications during the trial, if necessary [33].
Upon enrollment, participants were randomized to
one of three groups: a) EPA-rich fish oil supplement
(1060 mg EPA plus 274 mg DHA); b) DHA-rich fish oil
supplement (900 mg DHA plus 180 mg EPA); and c)
placebo. The aims and primary outcomes of the parent
study are reported in separate publications [33, 40]. The
primary outcome of the parent study, the Beck Depres-
sion Inventory score at 34–36 weeks gestation, and at
6–8 weeks postpartum, which was not influenced by ei-
ther fish oil intervention at any time point in pregnancy,
when compared with placebo [40].
Psychological assessments or instruments
Beck depression inventory
We administered two psychological instruments, the
Beck Depression Inventory and the Mini International
Neuropsychiatric Interview, to enrolled study partici-
pants at enrollment (12–20 weeks), at 26–28 weeks, at
34–36 weeks, and at 6–8 weeks postpartum. Study par-
ticipants self-completed the BDI. The BDI consists of 21
questions regarding depressive feelings (hopelessness
and irritability), cognitions (guilt, feelings of being pun-
ished) and physical symptoms (fatigue, weight loss) and
has been validated in the perinatal period. Higher total
scores indicate more severe depressive symptoms. The
BDI is ideal for repeat evaluation, as it is responsive to
changes over time. We used the Beck Depression Inventory
(BDI) to assess depression symptom severity [33, 40]. The
test characteristics of the BDI in the perinatal period have
been previously described [30, 31]. Normative values for
BDI scores previously established in our population were
used for the purpose of our sample size calculations [41].
Study staff with training in clinical psychology (masters
or doctoral student level) administered the Mini Inter-
national Neuropsychiatric Interview (MINI) in order to
diagnose major depressive disorder (MDD) and General-
ized Anxiety Disorder (GAD) [33, 40].
The MINI is a structured interview designed as a diag-
nostic tool for DSM-IV and ICD-10 psychiatric disor-
ders. We used the MINI at enrollment (12–20 weeks),
to identify ineligible participants. At subsequent visits
(26–28 weeks, 34–36 weeks, and 6–8 weeks postpartum)
we used the MINI to assess for development of major
depressive disorder and to facilitate referral to appropri-
ate mental health services. For our secondary outcomes
we evaluated major depressive disorder, generalized anx-
iety disorder, as well as the generalized anxiety question
on the MINI, “Have you worried excessively or been
anxious about several things over the past 6 months?”
We evaluated this anxiety question separately in order to
assess anxiety symptoms that may be important but that
did not meet criteria for generalized anxiety disorder.
Biomarkers
Maternal venous blood was drawn at enrollment at 12–20
weeks (n = 117) and at 34–36 weeks gestation (n = 112).
The blood was drawn after a 4 h fast. All blood samples
were processed within 12 h and aliquots of serum or
plasma were frozen at −70° Celsius under argon until
analysis.
Blood sample analyses from the parent study included
the omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) from serum. These analyses
have been previously described [33, 40]. For this second-
ary analysis, we measured serum 25-hydroxyvitamin D
(25-OH-D) in stored plasma aliquots. Although 1, 25-
Dihydroxyvitamin D (not 25-OH-D) is the biologically
active form of vitamin D, circulating levels of 1, 25-
Dihydroxyvitamin D are not a good representation of
tissue levels, and tissue levels are not easily measured. On
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the other hand, 25-OH-D is the major form of circulating
vitamin D and is highly stable for analysis from stored
serum or plasma. Thus, most of the current literature
uses 25-OH-D as the assessment of overall vitamin D
status [28, 42, 43]. This measurement was performed
using a 25-OH-D 125I Radioimmunoassay kit from
DiaSorin, Stillwater, Minnesota, U.S.A [44]. Inter-assay
variations have been shown to be <10 % at levels of
25-OH-D between 15–67 ng/ml.
Statistical analysis
We evaluated mean vitamin D levels and standard devia-
tions at 12–20 weeks and at 34–36 weeks and used
Pearson’s correlation to evaluate the relationship be-
tween time points. We used the T-Test procedure to
evaluate the relationship between vitamin D 1 at enroll-
ment and seasonality, with “winter” being defined as
“December through February”.
In our primary analysis, we assessed the relationship
between vitamin D as a continuous variable and BDI
scores at 12–20 weeks, 34–36 weeks and the 6–8 week
postpartum visits. Using a generalized linear models
(ANCOVA) approach we entered winter and vitamin D
at visit 1 into the model as predictors of the BDI score
at visit 1 (study entry), at 34–36 weeks gestation and at
6–8 weeks postpartum.
We used repeated measures ANOVA to fit the vitamin
D level at baseline and in late pregnancy to the square
root of the BDI score at visits 1, 2, 3, and 5, adjusting for
“winter”, baseline BDI, baseline vitamin D and most re-
cent vitamin D. We transformed the BDI by its square
root to correct for skewed (non-normal) distribution.
Evaluation of psychiatric diagnoses by the MINI diag-
nostic tool was analyzed using Fisher’s Exact test.
To compare outcomes according to vitamin D suffi-
ciency versus insufficiency in our population, we per-
formed a secondary analysis selecting a vitamin D level
of ≥ 20 ng/mL at enrollment (n = 98) as our reference
group and <20 ng/mL (n = 19) as our “low vitamin group.
We defined these two groups based upon assessment from
the Institute of Medicine that most individuals are assured
good bone health with levels that are 20 ng/ml or higher,
as well as the Endocrine Society’s Clinical Practice Guide-
line definition of vitamin D deficiency of 25 OH vitamin
D levels <20 [43, 45]. No threshold has been established
for prevention of other diseases hypothesized to be related
to vitamin D status [43, 45–47]. Of note, the Endocrine
Society has suggested a vitamin D target for pregnant
women of ≥30 ng/ml [43].
We used stepwise linear regression analyses to better
define the relationship between “low vitamin D” and
BDI score while adjusting for potentially confounding ef-
fects. Variables included in these analyses were those re-
lating to the parent study (serum DHA and EPA levels,
which have been hypothesized to be associated with de-
pressive symptoms [33, 40] along with other factors
thought to be potentially associated with depressive
symptoms (age, tobacco use, obesity [defined as BMI
≥30], initiation of anti-depressant medications). In this
model, low vitamin D and other variables were consid-
ered categorically (DHA <2.0 as % of total fatty acids,
EPA <0.1 as % of total fatty acids, age >35, positive to-
bacco use, BMI >30, and positive initiation of anti-
depressant medications). Because there are no published
normative values for DHA and EPA in pregnancy, we
chose to define low DHA as <2 (approximately 1 stand-
ard deviation below the mean in our sample), and low
EPA as <0.1 (also approximately 1 standard deviation
below the mean in our sample). We evaluated the asso-
ciation of vitamin D levels at visits 1 and 3 with “winter”,
using Fisher’s exact test.
We used descriptive statistics to compare characteristics
of the reference group and the “low vitamin D” group.
Student’s test was used for continuous variables that were
normally distributed, the Mann-Whitney test was used for
non-parametric comparison of ordinal variables, and
Fisher’s Exact test was used for rare categorical variables.
All statistical analyses were performed using SAS
Version 9.3 (SAS Institute, Inc., Cary, NC).
Results
In the parent study, 126 women were enrolled and were
randomly assigned to receive EPA-rich fish oil, DHA-
rich fish oil, or placebo. Of these, 8 women discontinued
trial participation entirely and were lost to follow up.
Plasma samples were available for 117 participants at
12–20 weeks and 112 participants at 34–36 weeks.
Complete study datasets (including all variables of inter-
est) were available for 105 participants. The flow of
study participants and blood samples is shown in Fig. 1.
The demographic characteristics of the cohort have been
previously described [40]. In brief, the study population
was 81.3% white, with African-Americans representing
8.5 % of the cohort. The remainder of the study cohort
were of Asian, Native American, Hispanic, or Pacific
Islander ethnicity. The ethnic and racial characteristics
did not differ significantly among the randomized groups
[40]. Because of the small proportion of non-white partici-
pants, with 8 % of the total cohort for the purpose of the
analyses, the non-white participants were combined. In
addition, our subjects were relatively homogeneous in so-
cioeconomic status, with at 89 % of our study population
having at least some college education.
Participants characteristics were stratified by possible
vitamin D deficiency (25 (OH) D <20 ng/mL) for descrip-
tive purposes (Table 1). The mean vitamin D level for the
aggregate study population was 28.17 ng/ml+/− 8.25 and
3.1.84 ng/ml +/− 10.63at 12–20 weeks and 34–36 weeks
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respectively. Vitamin D levels at 12–20 weeks were
strongly correlated with vitamin D levels at 34–36 weeks
(Pearson’s ρ = 0.60, P < .0001). Vitamin D levels drawn in
winter were significantly lower than vitamin D levels
drawn during other seasons (mean vitamin D =29.0 +/−
8.2 versus 26.5 +/− 7.6, P < 0.05).
As previously discussed, we selected a vitamin D level ≥
20 ng/mL (N = 98) for our reference group and <20 ng/
mL (N = 19) for our “low vitamin D” group for sub-
analysis. The “low vitamin D” group was younger (mean
age 27.8 years versus 30.8 years, P 0.03) and more likely to
report tobacco use (32 % versus 6 %, P 0.004). The
remaining descriptive characteristics of interest were not
significantly different between the two groups (Table 1).
The frequency of vitamin D <20 ng/ml at 12–20 versus
34–36 weeks was 16 % and 12 % of our total population.
Mean values and standard deviations for the two groups
are shown in Table 2.
For our primary outcome, we evaluated the relation-
ship between vitamin D levels at two time points and
BDI scores at 12–20 weeks, 34–36 weeks and 6–8 weeks
postpartum. Using analysis of covariance (ANCOVA),
and adjusting for season, (winter/non-winter), we found
that vitamin D at 12–20 weeks was a significant pre-
dictor of the BDI score at 12–20 (P < 0.05) weeks and at
34–36 weeks gestation (P < 0.05). For every one unit in-
crease in vitamin D in early pregnancy there was an
approximate 0.14 unit decrease in the BDI score at visit
1 (95 % confidence interval −0.26, −0.017) and visit 3
(−0.27, −0.011). Vitamin D at visit 34–36 weeks did not
significantly predict the BDI score at that same time point.
We next performed repeated measures analysis, evalu-
ating for association of the most recent vitamin D value
with the BDI score adjusting for winter, baseline BDI
score, most recent BDI score, most recent DHA level
and group assignment. The model was fit to the square
root of the BDI score due to skewed distribution. There
was a non-significant trend towards association of the
most recent vitamin D level with the BDI score (P = 0.07).
However, only the baseline BDI score was significantly
associated with the BDI score on repeated measure-
ments (P < 0.001).
When evaluating “low vitamin D” as a categorical vari-
able, there was no association seen between vitamin D
level at 12–20 weeks and BDI score at that time (P = 0.11)
or with postpartum BDI score (P = 0.97). However, “low
vitamin D” at enrollment was significantly associated with
higher BDI score at 34–36 weeks gestation (P = 0.05).
Because our study participants were drawn from a par-
ent study looking at omega-3 fatty acids (DHA and EPA)
and their relationship to depression, and to adjust for
other potential confounders, we conducted a stepwise lin-
ear regression to better understand the association of vita-
min D with the BDI score. In this adjusted model, “low
Fig. 1 Consort diagram
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vitamin D”, at visit 1 (again, as a categorical variable) was
associated with the BDI at 34–36 weeks’ gestation (P =
0.01), while there was a trend toward association of low
DHA (P = 0.06) and low EPA (P = 0.09) with higher BDI
scores at that time point as well (R2 for the model = 0.12).
There was no association between low vitamin D and
postpartum BDI scores in the regression analysis. The
remaining variables we evaluated (age, tobacco use,
obesity (BMI) and initiation of anti-depressant medi-
cations) did not significantly impact this model. That
is, age, tobacco use, BMI, and initiation of antidepres-
sant medications were not significantly associated
with the BDI scores. We found that 12 % of the vari-
ance in the BDI score at 34–36 weeks was predicted
by low vitamin D levels, low EPA, and low DHA at
12–20 weeks.
Vitamin D levels were not associated with a higher risk
of major depressive disorder, generalized anxiety dis-
order, or a positive response to anxiety question 1a at
any time. Of interest, 38.5 % of our study population re-
ported a positive response to anxiety question 1a at 34–
36 weeks, perhaps identifying this as a time of particular
vulnerability to such symptoms.
Discussion
Main findings
This study presents evidence that low vitamin D levels
in early pregnancy (12–20 weeks) are significantly asso-
ciated with higher depression symptom scores at in early
and late pregnancy in a group of women at risk for de-
pression. Conversely, we found that although there was
a trend toward an association of most recent vitamin D
levels with the BDI score in later pregnancy and postpar-
tum, this trend was not significant and largely disap-
peared after adjustment for the baseline BDI score. Low
vitamin D levels (at any time point) were not signifi-
cantly associated with higher postpartum depression
symptom scores.
Strengths and limitations
Our study had four main strengths, one of which was its
prospective, longitudinal study design, allowed for meas-
urement of depressive symptoms at several time points
during pregnancy, as well as at 6 weeks postpartum. An-
other strength of this study is that we were able to meas-
ure vitamin D longitudinally as well, both in early and
late pregnancy. A third strength of this study was that
we assessed both depression symptom scores (using the
BDI) as well as depression diagnoses (using the MINI).
Lastly an area of strength in this study was that it evalu-
ated women at risk for depression, allowing for our
outcome of interest (depressive symptoms) to be moder-
ately prevalent in our study cohort. The lack of associ-
ation observed between vitamin D level in early or late
pregnancy and the 6–8 week postpartum BDI score may
be explained by the complexity of the pathogenesis of
Table 1 Baseline Characteristics Stratified by Vitamin D level at
12–20 weeks
Parameter Vitamin D
≥20 ng/mL
Vitamin D
<20 ng/mL
P – value
(N = 98) (N = 19)
Age a0.03b
Mean, S.D. 30.8, 5.04 27.8, 5.04
Gravidity 0.17c
Mean, S.D. 2.36, 1.49 3.00, 1.91
Parity 0.27c
Mean, S.D. .89, 0.98 1.15, 1.12
Gestational age (weeks)
at enrollment
0.57b
Mean, S.D. 16.3, 2.41 16.7, 2.60
White N (percent) 82 (84) 14 (74) 0.38d
Non-White N (percent) 16 (16) 5 (26)
Self-reported history of
depression
1.00d
N (percent) 79 (81) 15 (79)
Reported tobacco use a0.004d
N (percent) 6 (6) 6 (32)
BMI 0.10c
Mean, S.D. 27.62, 6.82 31.00, 7.85
October-March at
enrollment
0.81d
N (percent) 55 (56) 10 (53)
EPA (as % of total
fatty acids)
0.11c
Mean, S.D .37, .21 .32, .24
DHA (as % of total
fatty acids)
0.44c
Mean, S.D. 3.18, 1.32 2.91, 0.80
BDI at baseline 7.4, 4.9 10.2, 7.1 0.11
S.D. standard deviation, BMI body-mass index, a = statistically significant
bStudent’s t-test
cMann-Whitney test
dFisher’s Exact test
Table 2 Vitamin D Characteristics
Parameter Vitamin D
≥20 ng/mL
Vitamin D
<20 ng/mL
12–20 weeks
n (percent) 98 (84) 19 (16)
Mean, S.D. 30.57, 6.65 15.78, 2.58
34–36 weeks
n (percent) 98 (88) 14 (12)
Mean, S.D. 34.36, 8.69 14.21, 4.37
S.D. standard deviation
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postpartum depression symptoms, or it may represent a
true negative finding.
Our study had four main limitations. This was a sec-
ondary analysis of a randomized, controlled trial, de-
signed to detect a reduction in BDI score following
intervention with omega-3 fatty acids. As such, results
must be interpreted with caution. Specifically, although
we attempted to control for confounding related to
omega-3 fatty acid levels, it is still possible that the inter-
vention, or even the participation in a clinical trial itself,
led to inappropriate conclusions. An additional limitation
of this study is that the sample size for the randomized
controlled trial was chosen based on the hypothesized re-
sponse to the omega-3 fatty acid interventions under
study on the BDI score, rather than as a study to detect an
association. Another potential limitation of the study is
that we used the BDI rather than the EPDS to assess de-
pressive symptom severity. We specifically chose the BDI
for this assessment in the parent trial because the ex-
pected BDI scores in our population had been previously
established [41]. An additional limitation of our study was
that we were unable to explore the potentially modulatory
effects of inflammatory cytokines on the relationship be-
tween vitamin D and depressive symptoms [23].
Our study found an association between low vitamin
D levels in early pregnancy and depressive symptoms
during pregnancy but not postpartum. In the published
literature, both low and high vitamin D levels have been
associated with perinatal depression, a finding that others
have hypothesized may be due to a 24-hydroxylase-based
degradation mechanism responding to abnormally high
concentrations of vitamin D [29].
The main finding of our study is that there exists a re-
lationship between low early-pregnancy vitamin D levels
and depression symptoms in early and late pregnancy in
women at risk for depression. Our regression model sug-
gested that 12 % of the variance in BDI score at 34–36
weeks was predicted by a combination of low vitamin D,
low EPA and low DHA levels in early pregnancy. Al-
though this may not appear to be a strong relationship,
for complex psychological and psychiatric diagnoses, this
magnitude of association may indicate a relationship
worthy of further investigation. Vitamin D supplementa-
tion is a low cost and safe intervention in pregnancy
[48]. If randomized studies show a benefit for vitamin D
for prevention or treatment of perinatal depression, sup-
plementation may benefit maternal fetal and neonatal
health [49, 50].
Conclusions
Our findings suggest that lower vitamin D levels in early
pregnancy are associated with depressive symptoms in
early and late pregnancy. This association may be attrib-
uted to a true effect of nutritional deficiency or alternately
might be related to differences in vitamin D metabolism
between women who are predisposed to depression and
those who are not. Important future areas of research
would include randomized controlled trials of vitamin D
supplementation for women who are screen for depres-
sion risk in early pregnancy and who are found to have
low vitamin D levels. Such future research should also
explore any potential interaction between inflammatory
cytokines and vitamin D on depression symptoms.
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